Survival from uveal melanoma in Western Australia 1981–2005

Background: The survival rates for patients diagnosed with uveal melanoma in Australia are unknown. Few long-term studies of uveal melanoma are available, and it is unclear whether their results are applicable to the Australian population. Design: Retrospective population-based study. Participants:...

Full description

Bibliographic Details
Main Authors: Chew, A., Spilsbury, Katrina, Isaacs, T.
Format: Journal Article
Published: Wiley-Blackwell Publishing Asia 2015
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/8985
_version_ 1848745819741618176
author Chew, A.
Spilsbury, Katrina
Isaacs, T.
author_facet Chew, A.
Spilsbury, Katrina
Isaacs, T.
author_sort Chew, A.
building Curtin Institutional Repository
collection Online Access
description Background: The survival rates for patients diagnosed with uveal melanoma in Australia are unknown. Few long-term studies of uveal melanoma are available, and it is unclear whether their results are applicable to the Australian population. Design: Retrospective population-based study. Participants: Patients diagnosed with uveal melanoma between 1981 and 2005 in Western Australia. Methods: Three hundred eight cases were included. Relative survival and Cox regression were performed. Variables tested for their predictive ability included patient age and sex, tumour-specific variables, and treatment modality. Main Outcome Measures: All-cause survival rates and relative survival rates of patients with diagnosed uveal melanoma. Results: Relative survival rates for the entire cohort were 88.2%, 81.4% and 71.4% at 3, 5 and 10 years, respectively. Predictors of worse survival included mixed-cell tumour morphology (hazard ratio [HR] = 2.1; P-value = 0.002), tumour location at the ciliary body (HR = 1.7; P-value = 0.029) and tumour apical height more than 5 mm (HR 1.9, P-value = 0.026). Of all patients who underwent enucleation, those diagnosed in 1998–2005 died twice as fast (HR = 2.3; P-value = 0.004). In the 17 patients with metastasis, the median survival time from date of diagnosis of metastasis was 3.1 months. Conclusions: These survival estimates are comparable to those reported for the USA, and more optimistic than those reported for most European-based studies. Tumour apical height, tumour site, tumour morphology and having an enucleation in certain calendar periods of diagnosis were independent predictors of survival. Survival prognosis for patients with diagnosed metastatic uveal melanoma is very poor.
first_indexed 2025-11-14T06:23:25Z
format Journal Article
id curtin-20.500.11937-8985
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:23:25Z
publishDate 2015
publisher Wiley-Blackwell Publishing Asia
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-89852019-02-19T05:35:29Z Survival from uveal melanoma in Western Australia 1981–2005 Chew, A. Spilsbury, Katrina Isaacs, T. uveal melanoma Intraorbital malignancy survival Background: The survival rates for patients diagnosed with uveal melanoma in Australia are unknown. Few long-term studies of uveal melanoma are available, and it is unclear whether their results are applicable to the Australian population. Design: Retrospective population-based study. Participants: Patients diagnosed with uveal melanoma between 1981 and 2005 in Western Australia. Methods: Three hundred eight cases were included. Relative survival and Cox regression were performed. Variables tested for their predictive ability included patient age and sex, tumour-specific variables, and treatment modality. Main Outcome Measures: All-cause survival rates and relative survival rates of patients with diagnosed uveal melanoma. Results: Relative survival rates for the entire cohort were 88.2%, 81.4% and 71.4% at 3, 5 and 10 years, respectively. Predictors of worse survival included mixed-cell tumour morphology (hazard ratio [HR] = 2.1; P-value = 0.002), tumour location at the ciliary body (HR = 1.7; P-value = 0.029) and tumour apical height more than 5 mm (HR 1.9, P-value = 0.026). Of all patients who underwent enucleation, those diagnosed in 1998–2005 died twice as fast (HR = 2.3; P-value = 0.004). In the 17 patients with metastasis, the median survival time from date of diagnosis of metastasis was 3.1 months. Conclusions: These survival estimates are comparable to those reported for the USA, and more optimistic than those reported for most European-based studies. Tumour apical height, tumour site, tumour morphology and having an enucleation in certain calendar periods of diagnosis were independent predictors of survival. Survival prognosis for patients with diagnosed metastatic uveal melanoma is very poor. 2015 Journal Article http://hdl.handle.net/20.500.11937/8985 10.1111/ceo.12490 Wiley-Blackwell Publishing Asia fulltext
spellingShingle uveal melanoma
Intraorbital malignancy
survival
Chew, A.
Spilsbury, Katrina
Isaacs, T.
Survival from uveal melanoma in Western Australia 1981–2005
title Survival from uveal melanoma in Western Australia 1981–2005
title_full Survival from uveal melanoma in Western Australia 1981–2005
title_fullStr Survival from uveal melanoma in Western Australia 1981–2005
title_full_unstemmed Survival from uveal melanoma in Western Australia 1981–2005
title_short Survival from uveal melanoma in Western Australia 1981–2005
title_sort survival from uveal melanoma in western australia 1981–2005
topic uveal melanoma
Intraorbital malignancy
survival
url http://hdl.handle.net/20.500.11937/8985